签约仪式现场 广医宣供图 去年12月，广州医科大学成果转化与产业孵化基金正式落地，这也是广东省首支聚焦医科院校科技成果 转化的孵化基金，初期投资规模1亿元。 签约仪式透露，基金将致力于构建覆盖"筛选-孵化-产业化"的全链条支持体系，而这一体系又将如何破 解医学类科研成果从实验室走向市场的"最后一公里"难题？ 前期投资1亿元，只为找到好项目 广州金控集团统筹谋划，广州健康产投基金负责金融运作，广州高新区投资集团提供产业资源支持，校 友企业链接产业网络与资本活力——签约现场，来自政府部门、金融机构、产业界、校友界的代表悉数 到场，彰显各方对于广医科技成果转化工作的重视与支持。 签约仪式上，一个数字被反复提及：1亿元。"成立时，大家都希望规模更大、资金更多，但还是要坚持 务实。"广州医科大学资产经营有限公司董事长、总经理林炜基表示，相比于钱，好项目才是关键。 何为好项目？记者了解到，成熟度是评价一个项目的重要指标，"项目是否可行、成果是否成熟、知识 产权状况如何等都是考量因素。"而其中，专利最为核心。 作为拥有数家附属医院的高校，广州医科大学早已建成创新药物研究开发平台，在创新药尤其是呼吸疾 病相关的药物研发方面有 ...

去年12月，广州医科大学成果转化与产业孵化基金正式落地，这也是广东省首支聚焦医科院校科技成果转化的孵化基金，初期投资规模1亿元。 签约仪式透露，基金将致力于构建覆盖"筛选-孵化-产业化"的全链条支持体系，而这一体系又将如何破解医学类科研成果从实验室走向市场的"最后一公 里"难题？ 前期投资1亿元，只为找到好项目 何为好项目？记者了解到，成熟度是评价一个项目的重要指标，"项目是否可行、成果是否成熟、知识产权状况如何等都是考量因素。"而其中，专利最为核 心。 作为拥有数家附属医院的高校，广州医科大学早已建成创新药物研究开发平台，在创新药尤其是呼吸疾病相关的药物研发方面有很好的基础，去年发布的抗 甲型流感1类新药昂拉地韦，正是高校携手广州国家实验室以及相关生物科技有限公司等单位推出的成果代表。 如今这一基金成立后，也将优先筛选经校内孵化项目立项委员会初筛且具备临床应用潜力的项目，利用大学的专业背景提升技术路线验证的可靠性，配置发 展阶段相对成熟的项目。 科创基金=科研经费？误区！ 如何把钱用在刀刃上？接受采访时，相关负责人表示，钱投出去"一定要确保技术是成熟的"。 客观来说，科研成果转化率不高是不少高校普遍存在的问 ...

Group 1: Market Overview - The market sentiment has improved, leading to a broad-based rebound in major indices, with the Shanghai Composite Index rising by 1.41% to close at 4123.09 points [5][7] - The Wind All A Index increased by 1.89%, while the ChiNext Index surged by 2.98%, indicating strong performance in the innovation and growth sectors [7][10] - Small-cap stocks outperformed larger stocks, with the CSI 1000 Index rising by 2.26%, while the CSI 50 Index only increased by 1.45% [8][10] Group 2: Industry Dynamics - A draft national standard for prepared dishes has been released, aiming to ensure food safety and promote high-quality development in the industry [24][25] - In January 2026, the sales of excavators in China saw a year-on-year growth of 49.5%, with domestic sales increasing by 61.4% and exports rising by 40.5% [26][27] Group 3: Company Updates - Nicheng Co., Ltd. (603775.SH) announced an investment to acquire a 10.89% stake in Dongfang Jinxin Co., Ltd. for 166 million yuan and plans to increase its investment by 100 million yuan [28][29] - Weizhi Xiang (605089.SH) is innovating its business model by testing a "downstream market first" approach and expanding its channel through a "city partner" plan targeting lower-tier markets [30][31] - Zhongsheng Pharmaceutical (002317.SZ) reported positive results from Phase III clinical trials for its innovative drug, Anladiwei, indicating effective treatment for influenza in children and adolescents [32][33]

绿通科技：绿通产业基金拟1000万元投资圣昊光电，后者主营光通信（核心股）芯片测试设备 东田微：拟投资4亿元建设全球研发中心及华南制造总部项目，主要从事研发光通信（核心股）精密光 学元器件等 爱旭股份：与Maxeon签订《专利许可协议》 赛力斯：与重庆市沙坪坝区人民政府签署合作协议，以蓝电汽车相关存量资产剥离出资设立标的公司 【重要事项】 沙河股份：拟2.74亿元购买晶华电子70%股份 构成重大资产重组（核心股） 杉杉股份：若重整成功，公司实际控制人将变更为安徽省国资委 永太科技：拟购买永太高新25%股权，宁德时代将成为公司股东 【投资&签约】 中兴通讯：拟出资2亿元认购粤港澳大湾区创业投资引导基金合伙企业份额 【经营】 长盈精密：人形机器人（核心股）精密零组件2025年营收约1亿元，为AI品牌方提供服务器数据传输铜 缆 恒瑞医药（核心股）：HRS-4642注射液纳入突破性治疗品种名单，目前国内外尚无同类药物获批上市 众生药业：控股子公司一类创新药昂拉地韦两项III期临床试验获积极结果 天成自控：子公司武汉天成收到国内头部某汽车企业乘用车座椅定点通知，项目生命周期5年，预计总 金额23亿元 股票频道更多独家策 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 出品：新浪财经上市公司研究院 作者：天利 | | 截至12月31日 | 截至9月30日 | | --- | --- | --- | | | 2024年 | 2025年 | | | (人民幣千元) | | | | | (未經濟計) | | 非流動資產 | | | | 物業、廠房及設備 | 1.605 | 1.026 | | 使用權資產 ... | | 9,048 | | 無形資産 . | 269 | 217 | | 預付款項、按金及其他應收款項 | 277 | 680 | | 非流動資產總值 | 2,151 | 10,971 | | 流動資產 | | | | 存貸 | 8.928 | 13.095 | | 預付款項、按金及其他應收款項 | 13.907 | 5.326 | | 以公允價值計量且其變動計入當期損益的金融資產 | 89.074 | 151.932 | | 定期存款 | 3.954 | 4.107 | | 現金及現金等價物 | 10.063 | 117.957 | | 流動資產總值 | 125,926 | 292,417 | 晚 ...

Group 1 - Seasonal influenza impacts approximately 1 billion people globally each year, with 3 to 5 million cases developing into severe illness and 290,000 to 650,000 deaths due to influenza-related respiratory diseases [1] - The domestic influenza treatment drug market is currently dominated by Dongyangguang Pharmaceutical with Oseltamivir, but new players are rapidly emerging since 2025 [1] - Zhengxiang Pharmaceutical is seeking to list on the Hong Kong Stock Exchange, having submitted its application on January 30, with CICC as its sole sponsor [2][4] Group 2 - Zhengxiang Pharmaceutical's antiviral drug, Marcilosavir, has already been approved for market release, distinguishing it from most other 18A companies [3] - The company was founded in 2018 and has undergone multiple rounds of financing, raising a total of 872 million RMB, with a post-investment valuation of 2.48 billion RMB as of January 2026 [4][5] - The company has a drug portfolio that includes six assets, with Marcilosavir being the core product, which is a new generation antiviral targeting influenza [10][12] Group 3 - The global market for influenza treatment and prevention drugs is projected to reach $4.8 billion by 2024, with China contributing $1.7 billion [16] - The Chinese market for antiviral drugs is expected to grow to 13.6 billion RMB by 2035, with PA inhibitors and other antiviral drugs accounting for 13 billion RMB [17] - Marcilosavir faces competition from several established products, including Roche's Baloxavir and others, with pricing set at 222 RMB per box, which is higher than some competitors [20] Group 4 - Zhengxiang Pharmaceutical reported zero revenue for 2024 and 400,000 RMB for the first nine months of 2025, primarily from regulatory support services for Marcilosavir [23] - The company incurred losses of approximately 145 million RMB for both 2024 and the first nine months of 2025, totaling around 290 million RMB in cumulative losses [23] - The company collaborates with a national CSO, Jichuan Pharmaceutical, to enhance market share through its established distribution network [24] Group 5 - The company has a total of 52 R&D personnel, with significant expenditures on drug development, amounting to 100 million RMB and 81.6 million RMB in R&D costs for the respective reporting periods [23] - As of November 2025, the company had cash and cash equivalents of 523 million RMB and term deposits of 141 million RMB [27] - The overall cash flow from operating activities showed a net outflow of 1.06 billion RMB for 2024, indicating financial challenges [28]

Group 1 - The flu season is currently at a high epidemic level in China, with a significant increase in the purchase of cold and flu medications across various regions, particularly in East China where orders for antiviral drugs have surged over 80% [1] - In central regions like Wuhan, the order volume for flu medications has increased by over 95%, with the specific antiviral drug, Marbofloxacin, seeing a 120% increase in orders [1] - The Chinese Center for Disease Control and Prevention has reported that the current flu epidemic is at a high level, prompting discussions on the appropriate use of medications to avoid excessive or inappropriate use [1] Group 2 - Common antiviral medications for flu include neuraminidase inhibitors such as Oseltamivir and Peramivir, as well as RNA polymerase inhibitors like Marbofloxacin, with different drugs having varying indications and treatment durations [2] - Oseltamivir is suitable for a wide range of patients, including those over 2 weeks old, with a standard treatment course of 5 days, extendable for severe or immunocompromised patients [2] - Marbofloxacin is indicated for patients aged 5 and above, requiring only a single dose for treatment [2] Group 3 - Specific groups of children may be considered for preventive antiviral treatment during flu outbreaks, including those with compromised immune systems or those who have not developed sufficient immunity after vaccination [3] - It is recommended that preventive medication be administered within 48 hours of exposure and continued for 7 days after the last exposure, although treatment is still advised even if started later [3] - Light symptom patients are advised to stay home and manage symptoms, while severe cases should receive early empirical antiviral treatment [3]

Core Viewpoint - In 2025, three new domestic influenza drugs, including those developed by renowned experts like Zhong Nanshan and Zhang Wenhong, will be launched, marking a significant milestone in China's pharmaceutical industry as it breaks the record of having no original research influenza innovation drugs [2][9]. Summary by Sections New Drug Launches - The new influenza drugs are priced between 180 to 320 yuan, comparable to the existing drug, Marbaviroc (速福达) [3][2]. - These new drugs claim to enhance efficacy, with some promising symptom relief within 18 hours and others offering a single oral dose that reduces fever within approximately 22 hours [2]. Market Challenges - Despite the promising features, the new drugs face significant challenges in replacing established medications like Oseltamivir and Marbaviroc, which have dominated the market [4]. - As of October 2025, the sales of the new domestic influenza drugs totaled less than 10 million yuan, while Oseltamivir and Marbaviroc combined sold nearly 8.5 billion yuan from January to October [5][14]. Industry Insights - Industry experts suggest that the new influenza drugs are largely "fast-follow" products, leading to concerns about market saturation and limited commercial viability [6]. - The new drugs primarily target patients aged 12 and above, while existing drugs like Oseltamivir can be used for younger patients, limiting the new drugs' market reach [12]. Sales Channels - Traditional sales channels, including hospitals and pharmacies, have shown limited contribution to the sales of new drugs, with online sales becoming increasingly important [14][18]. - E-commerce platforms have seen significant sales for the new drugs, with online sales accounting for over 51% of sales for some products [18]. Differentiation Factors - A key differentiating factor for the new drugs is their lower resistance rates compared to older medications, which may provide effective treatment options in cases of resistance to existing drugs [20][22]. - Current data indicates that resistance rates for influenza strains against Oseltamivir remain low, but ongoing monitoring is necessary as the drugs become more widely used [22].

Group 1 - Guangzhou has rapidly advanced in the global innovation landscape, ranking 6th in the "Nature Index - Research Cities" from 42nd in 2015, surpassing 36 cities in ten years [1] - In 2023, Guangzhou added 12 new global unicorn companies, making it the fastest-growing city in China for unicorns, maintaining the 4th position nationally for three consecutive years [1][2] - The "Shenzhen-Hong Kong-Guangzhou" innovation cluster has topped the global rankings in the 2025 Global Innovation Index, surpassing the long-standing leader, the "Tokyo-Yokohama" region [1] Group 2 - Guangzhou's innovation ecosystem is supported by a combination of talent, policies, and financial resources, with 84 universities and numerous research institutions contributing to its scientific output [2][3] - In 2024, Guangzhou published 70,843 research papers, a 10.86% increase year-on-year, leading in both volume and growth rate [2] - The city accounted for nearly half of the research output and one-third of the venture capital in the Shenzhen-Hong Kong-Guangzhou cluster, with 315 investment events totaling over 20 billion yuan [2] Group 3 - Guangzhou has established a "fund jungle" to support innovation, with a total of 2 trillion yuan in various funds aimed at boosting financial backing for tech projects [3] - The city has set up 44 sub-funds under its innovation fund, with a total paid-in capital exceeding 27 billion yuan, significantly amplifying investment in local projects [3] Group 4 - The "China Innovation and Entrepreneurship Competition" has been held in Guangzhou for ten consecutive years, fostering numerous tech startups and attracting over 35,000 participating companies [4] - The competition has helped over 1,000 companies secure nearly 50 billion yuan in equity financing, showcasing its role as a platform for tech enterprises [4] Group 5 - Guangzhou's innovation strategy has evolved over time, with significant achievements in drug development, including the approval of the world's first targeted flu drug, Anladiwei [5][6] - The city has seen a surge in new business registrations in strategic emerging industries, with growth rates exceeding 100% in sectors like aerospace and quantum technology [6][8] Group 6 - The city's focus on IAB (Information Technology, Artificial Intelligence, Biomedicine) and NEM (New Energy, New Materials) industries has been strategic, leveraging existing strengths in automotive and electronics [7] - Guangzhou's R&D expenditure surpassed 100 billion yuan for the first time in 2024, marking a decade of continuous growth in R&D intensity among first-tier cities [8]

Economic Growth and Development - Guangzhou aims to elevate its economic scale, targeting a GDP of 3.1 trillion yuan by 2024, with an expected GDP increment of 700 billion yuan during the "14th Five-Year Plan" period [1] - The city has maintained a "double trillion, double growth" trend in social retail sales and foreign trade, becoming the third city in China to achieve this milestone [1] - The average annual disposable income growth for urban and rural residents is 5.13% and 6.95% respectively, both exceeding GDP growth [1] Talent and Employment - Guangzhou is implementing the "Million Talents Gather in South Guangdong" initiative, focusing on attracting high-level foreign talent, ranking among the top three in national talent attraction [1] - The city has added 1.634 million new jobs, emphasizing a strategy prioritizing employment [1] Technological Advancements - Guangzhou has made significant strides in technology, with its global ranking in the "Nature Index - Research Cities" rising to 6th, and the "Shenzhen-Hong Kong-Guangzhou" innovation cluster ranking first globally [1] - The city has developed key technologies, including the first domestically built ocean drilling vessel and a new flu drug, showcasing its commitment to national strategic technology [2] Infrastructure and Connectivity - The Nansha area has seen its GDP surpass 230 billion yuan, with a population nearing 1.3 million, attracting over 3,500 Hong Kong and Macau enterprises [2] - Baiyun Airport has become one of China's three comprehensive international aviation hubs, with passenger throughput increasing from 43.77 million in 2020 to 76.37 million by 2024, a growth of 74% [2]